202 related articles for article (PubMed ID: 32826245)
1. Distinct Prognostic Values of the mRNA Expression of Glucose Transporters in Non-Small Cell Lung Cancer.
Du H; Liu Y; Yuan Y; Zhang Y; Geng H
Ann Clin Lab Sci; 2020 Jul; 50(4):481-489. PubMed ID: 32826245
[TBL] [Abstract][Full Text] [Related]
2. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
3. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
5. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma.
Kaishang Z; Xue P; Shaozhong Z; Yingying F; Yan Z; Chanjun S; Zhenzhen L; Xiangnan L
Life Sci; 2018 Dec; 215():159-169. PubMed ID: 30391462
[TBL] [Abstract][Full Text] [Related]
7. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
You Q; Guo H; Xu D
Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
[TBL] [Abstract][Full Text] [Related]
8.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
10. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma.
Zhou H; Zhu Y; Qi H; Liang L; Wu H; Yuan J; Hu Q
Aging (Albany NY); 2021 Feb; 13(4):5312-5331. PubMed ID: 33535184
[TBL] [Abstract][Full Text] [Related]
12. Prognostic roles of mRNA expression of notch receptors in non-small cell lung cancer.
Xiong J; Zhang X; Chen X; Wei Y; Lu DG; Han YW; Xu J; Yu D
Oncotarget; 2017 Feb; 8(8):13157-13165. PubMed ID: 28061457
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
Gong L; Liu Q; Jia M; Sun X
Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
Zhang JT; Lin YC; Xiao BF; Yu BT
Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
[TBL] [Abstract][Full Text] [Related]
15. Diverse CBX family members as potential prognostic biomarkers in non-small-cell lung cancer.
Xie X; Ning Y; Long J; Wang H; Chen X
FEBS Open Bio; 2020 Oct; 10(10):2206-2215. PubMed ID: 32894652
[TBL] [Abstract][Full Text] [Related]
16. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of glucose transporters in human oral squamous cell carcinoma cells.
Paolini R; Moore C; Matthyssen T; Cirillo N; McCullough M; Farah CS; Botha H; Yap T; Celentano A
J Oral Pathol Med; 2022 Sep; 51(8):679-683. PubMed ID: 35920070
[TBL] [Abstract][Full Text] [Related]
18. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
[TBL] [Abstract][Full Text] [Related]
19. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y
J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717
[TBL] [Abstract][Full Text] [Related]
20. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
